Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Anakinra/canakinumab

Hidradenitis suppurativa and no improvement: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lopez SanzP, et al. Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab. Clinical and Experimental Dermatology 48 : 535-536, No. 5, Jan 2023. Available from: URL: http://doi.org/10.1093/ced/llad003 Lopez SanzP, et al. Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab. Clinical and Experimental Dermatology 48 : 535-536, No. 5, Jan 2023. Available from: URL: http://​doi.​org/​10.​1093/​ced/​llad003
Metadaten
Titel
Anakinra/canakinumab
Hidradenitis suppurativa and no improvement: case report
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43484-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Elasomeran

Case report

Mesalazine

Case report

Warfarin

Case report

Multiple drugs